Does IP chemotherapy plus bevacizumab improves progression-free survival in women with optimally debulked ovarian cancer?

Paclitaxel 80 mg/m2 weekly IV + carboplatin AUC 6 IV q3wks x6 cycles

bevacizumab 15 mg/kg IV starting cycle 2 + maintenance

(1) Paclitaxel 80 mg/m2 weekly IV + carboplatin AUC 6 IP q3wks x6 cycles

bevacizumab 15 mg/kg IV starting cycle 2 + maintenance

(2) Paclitaxel 135 mg/m2 IV day 1 + cisplatin 75 mg/m2 IP day 2 + paclitaxel 60 mg/m2 IP day 8 q3wks x6 cycles

bevacizumab 15 mg/kg IV starting cycle 2 + maintenance

PFS

stage II - IV epithelial ovarian cancer

IP Carboplatin vs IP Cisplatin vs IV Carboplatin:

median f/u: 84.4 mos

median PFS: 27.4 vs 26.2 vs 24.9 months (NS)

median OS: 78.9 vs 72.9  vs 75.5 months (NS)

G3 adverse events: 17.2% vs 17.7% vs 11.5% (SS)

G3 HTN: 14% vs 20.5% vs 12%

G3 N/V: 5% va 11% vs 5%

No increases in bowel complications with IP chemo